Skip to main content
    E

    Enlivex Therapeutics Ltd (ENLV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.15
    +0.03 (+2.68%)

    Market Cap: $1.72M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Enlivex Therapeutics Ltd (ENLV) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Enlivex Therapeutics (ENLV) has a market cap of $1.72M and an enterprise value of $13.07M. Its share count is up 1115.64% from a year earlier. Its net debt of $11.36M equals 662.02% of its market cap.

    Total Valuation

    Enterprise value is 662.02% above the market cap, as debt exceeds cash.

    Market Cap$1.72M
    Enterprise Value$13.07M
    Latest price (Nov 17, 2026)$1.15

    Key Dates

    The next earnings report is expected on Mar 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 23, 2027 (expected)
    Last Earnings DateSep 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 7.63% in the quarter ended Jun 30, 2026 and grew 285.19% a year over 2 years.

    Shares Outstanding1.21M
    Shares Change (YoY)+1115.64%
    Shares Change (QoQ)+7.63%
    Share Count Growth (2Y CAGR)+285.19%

    Price Statistics

    The stock is down 99.52% over 52 weeks and trades 79.97% below its 50-day average.

    Beta (1Y)1.71
    52-Week Change-99.52%
    1-Month Change-65.34%
    3-Month Change-95.85%
    6-Month Change-99.32%
    5-Year Change-99.91%
    10-Year Change-99.99%
    Total Return (1Y)-99.52%
    Total Return (3Y CAGR)-85.98%
    Total Return (5Y CAGR)-77.48%
    Return vs SPY (1Y)-111.07%
    Max Drawdown (1Y)-99.61%
    Max Drawdown (3Y)-99.89%
    Sharpe Ratio (1Y)-4.56
    Correlation with SPY (1Y)0.20
    50-Day Average$5.74
    200-Day Average$124.31
    52-Week Range$1.00 to $316.80
    RSI (14 Days)14.9
    Average Volume (20 Days)157.51K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 119.39x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio119.39x
    Quick Ratio119.39x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -0.30% over the last 12 months, against a 5-year average of -41.15%.

    Return on Equity (ROE)80.31%
    Return on Assets (ROA)63.89%
    Return on Invested Capital (ROIC)-0.30%
    ROE (5Y Average)-33.61%
    ROA (5Y Average)-28.24%
    ROIC (5Y Average)-41.15%

    Taxes

    Income tax took 23.23% of pretax income over the last 12 months.

    Income Tax (TTM)$1.24B
    Effective Tax Rate23.23%

    Scores

    ENLV has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Operating Income-$20.56M
    Pretax Income$5.35B
    Net Income$4.11B
    Reported EPS (TTM)-$65.76

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.59% of the $4.90B in total assets.

    Cash and Equivalents$5.52M
    Total Debt$16.88M
    Net Debt$11.36M
    Net Debt Per Share$9.40
    Working Capital$3.72B
    Shareholder Equity$3.90B
    Book Value Per Share$3,226.12
    Tangible Book Value$2.75B
    Tangible Book Per Share$2,277.04
    Total Assets$4.90B
    Total Liabilities$1.00B

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $39.38K of capital spending, operating cash flow left -$15.84M of free cash flow.

    Operating Cash Flow-$15.80M
    Capital Expenditures$39.38K
    Free Cash Flow-$15.84M
    FCF Per Share-$10.34
    Depreciation and Amortization$346.00K

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+7617.83%
    Tangible Book Per Share Growth (2Y CAGR)+6352.38%

    Revenue and profit by year

    Dividends and Yields

    ENLV does not pay a dividend. Its free cash flow yield is -1140.21%.

    FCF Yield-1140.21%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-16 reverse split on Oct 27, 2026.

    Last Split DateOct 27, 2026
    Split TypeReverse split
    Split Ratio1:16

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ENLV

    What is ENLV's market cap?

    Enlivex Therapeutics has a market cap of $1.72M. Its enterprise value, which adds debt and subtracts cash, is $13.07M.

    How many shares of ENLV are outstanding?

    Enlivex Therapeutics has 1.21M shares outstanding. The count is up 1115.64% from a year earlier.

    Does ENLV pay a dividend?

    No. Enlivex Therapeutics does not pay a dividend.

    How much debt does ENLV have?

    Enlivex Therapeutics has $16.88M of total debt and $5.52M of cash and equivalents, a net debt position of $11.36M.